Related Experiment Video

Updated: May 28, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Current medical treatments for juvenile idiopathic arthritis

Nicolino Ruperto1, Alberto Martini

  • 1Pediatria II e Reumatologia, Istituto G Gaslini Genoa, University of Genoa Genoa, Italy.

Frontiers in Pharmacology
|October 21, 2011
PubMed

Insights

Juvenile idiopathic arthritis (JIA) is not a single disease but a group of childhood arthritic conditions. Advances in biological treatments and research networks have improved JIA clinical trials and therapies.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Clinical Trials

Background:

  • Juvenile idiopathic arthritis (JIA) is an exclusion diagnosis for arthritis starting before age 16, persisting over 6 weeks, with unknown origin.
  • JIA is distinct from adult rheumatoid arthritis, presenting unique challenges in diagnosis and treatment.
  • Recent advancements in biological therapies have significantly altered treatment outcomes and patient expectations for JIA.

Purpose of the Study:

  • To review the methodological approaches for conducting clinical trials in JIA.
  • To provide an overview of current drug treatments available for JIA.
  • To highlight the impact of research networks and legislation on JIA studies.

Main Methods:

  • Review of existing literature on JIA clinical trials and therapeutic strategies.
  • Analysis of methodological advancements in pediatric rheumatology research.
  • Synthesis of data on current pharmacological interventions for JIA.

Main Results:

  • The landscape of JIA treatment has been transformed by biological therapies.
  • Improved methodologies and outcome measures enhance the reliability of JIA clinical trials.
  • International collaboration and legislative support have accelerated JIA research.

Conclusions:

  • Clinical trials in JIA benefit from robust methodologies and validated outcome measures.
  • Biological treatments offer improved responses and new therapeutic expectations for JIA patients.
  • Continued research and collaboration are crucial for advancing JIA management.

Keywords:
biological agentsjoint damagejuvenile idiopathic arthritissmall molecules

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...